PMID
int64 35.7M
36.4M
| Title/Abstract
stringlengths 22
8.78k
| MeshTerms
stringlengths 7
101
| SemanticTypes
stringlengths 4
64
|
|---|---|---|---|
36,290,946
|
progress develop biosensor base peptid copper coordin interact copper ion activ center natur enzym play import role mani physiolog process copper ion base catalyst mimic activ enzym wide use field industri catalysi sens devic import class small biolog molecul peptid advantag easi synthesi excel biocompat low toxic good water solubl peptid copper complex exhibit characterist low molecular weight high tenabl uniqu catalyt photophys properti biosensor peptid copper complex signal probe promis applic prospect environment monitor biomed analysi diagnosi review discuss design applic fluoresc colorimetr electrochem biosensor base peptid copper coordin interact
|
D003300;D015374
|
T123;T121;T075;T196;T059
|
36,290,945
|
g optrod bio interfac non invas optic cell stimul design evalu biocompat potenti efficaci biolog applic reli bio interact graphen nanoparticl biolog tissu analyz modul cellular devic level activ requir non invas electr stimul cell address need g optrod bio interfac base graphen develop devic use light stimul cell without modifi genet code optoelectron capabl particular capac transform light energi electr energi maintain throughout procedur neural stimul g optrod also studi thin film rang substrat design function small scale studi examin impact g optrod base substrat design optic stimul pheochromocytoma pc graphen electrod known g optrod respons convert light electr puls stimul effect g optrod bio interfac provid stimulus independ wavelength rang sensit chang illumin author perform comprehens investig base correct effect medic vitro employ substrat base g optrod biointerfac substrat base system author proven graphen biocompat pc cell cultur graphen day base find nm nm thick g optrod studi possibl use biolog artifici retin applic find studi highlight signific biocompat select use g optrod biomed purpos
|
D006108
|
T196;T109
|
36,290,944
|
ingeni fabric ag fill porous anod alumina film power ser substrat effici detect biolog organ molecul surfac enhanc raman scatter ser wide use effect detect various biolog organ molecul detect method need analyt adsorb onto specif metal nanostructur eg ag nanoparticl substrat contain structur call ser substrat user friend peopl implement adsorpt subsequ ser detect report power ser substrat base effici fabric ag fill anod aluminum oxid aao film film contain mani nanopor small grown inter pore gap nm substrat creat electrochem deposit silver nanopor without addit pore widen process usual need convent two step aao fabric creat substrat contain well separ ag nanoparticl quit small inter particl gap high number densiti cm use one step anod togeth omit addit pore widen improv throughput substrat fabric substrat provid low concentr detect limit high ser enhanc factor rhodamin g rg effect detect biolog organ molecul substrat demonstr analyt adenin glucos rg eosin methylen blue result allow us take one step toward success commerci aao base ser substrat
|
D012834;D053768
|
T196;T073
|
36,290,943
|
clinic applic epitheli sodium channel enac biomark arteri hypertens arteri hypertens htn global public health concern import risk factor cardiovascular diseas renal failur previous report overexpress enac plasma membran human platelet hallmark htn doubl blind studi open popul n evalu sensit specif diagnost assay base gold nanoparticl aunp conjug antibodi epitheli sodium channel enac express platelet detect use fluoresc anti enac secondari antibodi spectrofluorometri use cutoff valu aunp anti enac assay confirm diagnosi patient clinic htn detect patient previous undiagnos htn although shortcom term accur discrimin healthi individu patient htn still need resolv propos aunp anti enac assay could use initi screen earli diagnosi critic improv opportun clinic manag htn
|
D053768;D006973
|
T047;T073
|
36,290,942
|
colorimetr detect sar cov virus covid artifici saliva use polydiacetylen paper strip spread resurg sar cov virus covid diseas threaten human health social relat prevent covid diseas part reli fabric low cost point care poc sens technolog rapid select detect sar cov virus report colorimetr paper base polydiacetylen pda biosensor design detect sar cov spike protein artifici saliva analyt character pda sensor use nmr ft ir spectroscopi show correct structur elucid pcda nhs conjug pda sensor platform contain n hydroxysuccinimid ester pentacosadiyno acid pcda nhs divid three experiment pcda nhs concentr group optim perform sensor optim pcda nhs molar concentr determin pda sensor work color chang blue red colorimetr output immobil antibodi bind sar cov spike protein saliva sampl result show pda sens platform abl rapid qualit detect sar cov spike protein within concentr rang ngml four hour incub investig ph temperatur show minim influenc pda sensor detect covid diseas exposur sar cov spike protein smartphon imag pda sensor use assess sensor output use red chromat shift rcs signal respons result indic potenti practic use pda sensor design rapid colorimetr detect covid diseas develop countri limit access medic test
|
D000086382;D015374
|
T075;T047;T059;T067
|
36,290,941
|
silico investig snr dermi sensit optimum dual channel near infrar glucos sensor design differ skin color diabet serious health condit requir patient regular monitor blood glucos level make develop practic compact non invas techniqu essenti optic glucos sensor specif nir sensor advantag non invas compact inexpens user friend devic howev sensor low accuraci yet adopt healthcar provid previous work introduc non invas dual channel techniqu nir sensor long channel util measur glucos level inner skin dermi layer short channel use measur nois signal superfici skin epidermi layer work investig use dual nir channel patient differ skin color ie differ melanin concentr also adopt mont carlo simul model take consider differ differ skin layer term blood content water content melanin concentr epidermi layer skin optic proprieti basi signal nois ratio well sensit epidermi dermi layer suggest select wavelength sourc detector separ optim nir channel differ skin melanin concentr work facilit improv design compact non invas nir glucos sensor util patient differ skin color
|
D012880;D008543
|
T123;T109;T042
|
36,290,940
|
enhanc respons foodborn pathogen detect au nanoparticl decor zno nanosheet gas sensor listeria monocytogen hazard foodborn pathogen abl caus acut mening enceph sepsi human effici detect hydroxi butanon verifi biomark exhal listeria monocytogen feasibl evalu whether bacteria contain food herein develop outstand hydroxi butanon gas sensor base microelectromechan system use auzno ns sens materi work zno nanosheet synthes hydrotherm reaction au nanoparticl nm prepar via oleylamin reduct method ultrason treatment carri modifi au nanoparticl onto zno nanosheet xrd bet tem xps use character morpholog microstructur catalyt structur specif surfac area chemic composit respons auzno ns sensor vs ppm hydroxi butanon c moreov sensor present fast responserecoveri time great select outstand limit detect lower ppm work full promis develop nondestruct rapid practic sensor would improv listeria monocytogen evalu food
|
D015034;D053768;D000080745
|
T121;T197;T073
|
36,290,939
|
dual color fluoresc hydrogel microspher combin smartphon visual detect lactat sinc difficult human eye distinguish two ident color lt variat bright mono color fluoresc hydrogel microspher limit detect lactat herein prepar novel dual color fluoresc hydrogel microspher achiev hue transform microspher prepar introduc fluoresc nanoparticl refer signal cdte qds use respons signal use smartphon imag process softwar collect analyz data way signal lactat convert rgb red green blue valu quantit read within rg valu microspher linear relationship logarithm lactat concentr moreov color card lactat detect prepar color chang concentr lactat could easili read nake eye worth mention method success appli screen patient hyperlactatemia
|
D019187;D045663
|
T197;T073
|
36,290,938
|
electrochem microneedl innov instrument health care signific part drug therapi mode drug transport attract worldwid attent effici drug deliveri method mark improv drug absorpt rate also reduc risk infect recent microneedl combin advantag subcutan inject administr transderm patch administr painless also high drug absorpt effici addit microneedl base electrochem sensor uniqu capabl continu health state monitor play crucial role real time monitor various patient physiolog indic therefor common appli laboratori hospit varieti report regard electrochem microneedl howev comprehens introduct new electrochem microneedl still rare herein signific work electrochem microneedl past two year summar main challeng face electrochem microneedl futur develop direct propos
|
D057968;D009339
|
T074
|
36,290,937
|
high densiti gold nanoparticl implant mgfe ldh nanoflow assist later flow immuno dipstick assay visual detect human epididym protein timeli accur diagnosi diseas higher patient surviv rate human epididym protein great signific biomark concern reflect ovarian cancer herein prepar novel optic label use later flow immuno dipstick assay lfia sensit visual detect implant hydrophob gold nanoparticl au nps high densiti mgfe ldh nanoflow mf nfs mf nfs larg specif surfac area high poros abund activ bind site stabl structur employ first time templat direct anchor au nps organ phase simpl modif optim amount branch polyethyleneimin could mf au nfs dispers aqueous phase also amino function group introduc surfac facilit subsequ antibodi coupl step limit detect reach pm detect rang pm work initi explor mf nfs use load signal label ideal stabil signal amplif capabl great improv practic lfia highlight import role field rapid diagnost
|
D006046;D053768
|
T121;T196;T073
|
36,290,936
|
ho tio nanobelt electrod high select sensit detect cancer mirna design engin effect electrod materi critic develop electrochem sensor present studi ho tio nanobelt synthes alkalin hydrotherm process structur morpholog investig x ray diffract xrd field emiss scan electron microscop fesem measur ho tio nanobelt show distinct enhanc reflect peak rough surfac use electrochem select sens various cancer mirna prostat cancer mir osteosarcoma mir pancreat cancer mir voltammetr measur show oxid peak v three differ cancer biomark respect detect limit low result suggest ho tio nanobelt use activ materi detect earli cancer vitro screen anticanc drug molecular biolog research
|
D035683;D009369
|
T123;T191;T114
|
36,290,935
|
design optim magneto plasmon sandwich biosensor integr within microfluid devic design magneto plasmon biosensor immunodetect antigen minut sampl volum spheric gold nanoparticl aunp magnet bead mb conjug goat anti rabbit igg antibodi ab capabl recogn model target rabbit igg rigg aunp bioconjug use optic detect probe mb one use captur probe addit target analyt follow detect probe result format sandwich immunocomplex separ unbound aunp ab conjug applic extern magnet field readout execut either direct indirect way measur uv visibl spectrum fraction special design microcel dose respons curv establish optic signal immunocomplex unbound aunp ab conjug fraction final assay transpos microfluid cell special design enabl easi separ immunocomplex aunp ab conjug fraction subsequ analysi latter fraction achiev quantif analyt ngml concentr rang
|
D053768;D015374
|
T059;T073;T075
|
36,290,934
|
state art advanc nanomedicin diagnosi treatment bladder cancer bladder cancer common malign tumor urinari system cystoscopi urin cytolog ct routin diagnost method howev problem low sensit difficulti stage must urgent supplement novel diagnost method surgeri intraves instil system chemotherapi radiotherapi main clinic treatment bladder cancer difficult convent treatment deal tumor recurr progress drug resist addit treatment agent usual defect poor specif distribut abil target tumor tissu side effect rapid develop nanomedicin brought hope treatment bladder cancer reduc side effect enhanc tumor inhibit effect anti drug resist overal review new progress nano platform diagnosi treatment bladder cancer
|
D001749
|
T191
|
36,290,933
|
revers migrat fluoresc probe precis dynam evalu cell mitochondri membran potenti mitochondri membran potenti mmp mito provid charg gradient requir mitochondri function key indic cellular health chang mmp close relat diseas monitor mmp thus vital patholog studi drug develop howev current fluoresc probe mmp reli sole cell fluoresc intens thus restrict poor photost render suitabl long term dynam monitor mmp herein mmp respons fluoresc probe pyrrolyl quinolinium pq capabl revers migrat mitochondria nucleolus develop demonstr dynam evalu mmp fluoresc pq transloc mitochondria nucleoli mmp decreas due intrins rna specif import transloc revers cytoplasm nucleolus fluoresc intens ratio posit correl mmp method avoid negat influenc photost imag paramet various situat mmp monitor real time even without control addit long term dynam evalu mmp demonstr hela cell use pq oxid environ studi expect give impetus develop mitochondria relat diseas diagnosi drug screen
|
D005456;D012313
|
T130;T114
|
36,290,932
|
upconvers fluoresc nanoprob base fret sensit determin shigella shigella typic foodborn pathogen strong surviv environ food lead infecti diseas yet rapid detect technolog high select sensit remain challeng studi complementari strand modifi upconvers nanoparticl ucnp offer stabl yellow green fluoresc nm excit nm laser import shigella aptam modifi gold nanoparticl gnps form au bond act fluoresc reson energi transfer fret donor recognit element bind specif shigella signific quench fluoresc complementari strand modifi ucnp result fluoresc develop nanoprob increas linear increas shigella wide rang cfuml detect limit low cfuml moreov fabric upconvers fluoresc nanoprob achiev shigella detect contamin chicken without enrich h
|
D052157;D053768;D053758;D012760
|
T007;T073;T114
|
36,290,931
|
innov sandwich type biosensor toward sensit select monitor arachidonoylglycerol human plasma sampl use p cd aunp ddt amplific agent new immuno platform recognit endocannabinoid real sampl work ag success detect human plasma sampl use new sandwich type electrochem immun devic base poli cyclodextrin p cd function aunp ddt toluidin blue p cd ensur bioactiv stabil immobil ag antibodi provid broad surfac effici immobil biotinyl antibodi complet top section immunosensor report hrp conjug antibodi ag secondari antibodi ab attach surfac glassi carbon electrod gce modifi p cd well primarili biotinyl antibodi ab biosensor fabric process monitor use field emiss scan electron microscop fe sem ed method use differenti puls voltammetri techniqu immunosensor util detect ag real sampl suggest interfac increas surfac area allow immobil larg quantiti anti ag antibodi also improv biocompat stabil electr conduct final suggest immunosensor limit quantit determin ngl linear rang ngl result show suggest bioassay util diagnosi ag clinic sampl uniqu ultrasensit electrochem biodevic
|
D015374;D053768;D047392
|
T059;T073;T075;T109
|
36,290,930
|
silicon photomultipli high dynam rang high sensit sensor bio photon applic work overview silicon photomultipli sipm view defin import bio photon clinic applic sipm benchmark common photodetector name pin diod avalanch photodetector apd compar respect import circuit design paramet shown care select design bias voltag overvoltag gain defin compon devic integr micro optic allow sipm detector achiev consider sensit auto fluoresc af detect wide dynam rang low optic power pw w sipm manag bias voltag v v dc system integr optimis sensit enhanc bio photon research area af detect intraop exampl brain tumour margin
|
D055095;D017785
|
T090;T167
|
36,290,929
|
neonicotinoid microspher immunosens profil applic honeybe bee relat matric neonicotinoid common use insecticid due effect howev non target insect especi bee also affect neonicotinoid therefor neonicotinoid applic contribut declin bee popul worldwid present studi describ develop novel competit fluoresc microspher base suspens immunoassay neonicotinoid profil applic bee essenti bee relat matric use multi analyt profil xmap technolog construct neonicotinoid microspher immunoassay nmia neonicotinoid ovalbumin conjug coupl uniqu fluoresc paramagnet microspher compet free neonicotinoid present test sampl interact correspond specif antibodi total five independ nmia develop detect imidacloprid acetamiprid clothianidin thiacloprid thiamethoxam dinotefuran nitenpyram imidaclothiz limit detect ngml ngml ngml ngml ngml ngml ngml ngml respect develop nmia appli fortifi matric includ surfac water pollen honey honeybe neonicotinoid except dinotefuran could sensit detect test environment matric bee sensit ngml water ngg solid materi nmia provid rapid profil method common neonicotinoid includ ban european union outdoor use develop method contribut healthi sustain beekeep global via applic apiari environ
|
D007306
|
T131
|
36,290,928
|
stage skin cancer base hyperspectr microscop imag machin learn skin cancer common type cancer general divid basal cell carcinoma bcc squamous cell carcinoma scc malign melanoma mm incid skin cancer continu increas worldwid recent year earli detect great reduc morbid mortal hyperspectr microscop imag hmi technolog use power tool skin cancer diagnosi reflect chang physic structur microenviron sampl differ hmi data cube base spectral data work studi stage identif scc influenc select region interest roi stage result scc stage identif process optim result correspond standard normal variat transform snv spectra preprocess partial least squar pls dimension reduct hold method dataset partit random forest rf model stage identif highest stage accuraci kappa valu compar stage result base spectral characterist nuclear compart peripher region spectral data nuclear compart found contribut accur stage scc
|
D012878;D002280;D008545;D002294
|
T191
|
36,290,927
|
biosensor drug deliveri oncotheranost use inorgan synthet biogen magnet nanoparticl magnet nanocarri attract attent translat oncolog due abil employ tumor diagnost therapi review summar data applic synthet biogen magnet nanoparticl mnps oncolog theranost relat area basic type mnps includ synthesi approach structur physicochem properti discuss properti synthet mnps biogen mnps compar regard antitumor therapeut effici diagnost potenti biocompat cellular toxic compar analysi demonstr synthet biogen mnps could effici use cancer theranost includ biosensor drug deliveri time reduc toxic biogen particl note make advantag vivo applic drug deliveri mri imag tumor adapt surfac modif base natur biochem process also note well good compat tumor cell prolifer advanc bionanotechnolog field lead implement mnps clinic trial
|
D058185;D053758;D015374;D009369
|
T073;T075;T191;T059;T130
|
36,290,926
|
cholesterol chip studi cholesterol protein interact use spr cholesterol import lipid anim membran bind hydrophob pocket within mani solubl protein transport protein membran bound protein studi cholesterol protein interact aqueous solut complic cholesterol low solubl often requir organ co solvent surfact addit report synthesi biotinyl cholesterol immobil deriv streptavidin chip surfac plasmon reson spr use measur kinet cholesterol interact cholesterol bind protein hedgehog protein tyrosin phosphatas b
|
D020349;D053823
|
T063;T123;T116
|
36,290,925
|
sensit immunodetect assay use antibodi specif staphylococc enterotoxin b produc baculovirus express staphylococc enterotoxin b seb potent bacteri toxin caus inflammatori stimul toxic shock thus necessari detect seb food environment sampl develop sensit immunodetect system use monoclon antibodi mab studi first employ baculovirus express vector system bev produc recombin wild type seb bev facilit high quantiti pure seb product suspens cultur insect cell seb produc character mass spectrometri analysi seb stabl c least year maintain puriti util mous immun generat mab optim pair mab non competit seb select sandwich enzym link immunosorb assay base immunodetect limit detect immunodetect method ngml moreov display higher sensit detect seb commerci avail immunodetect kit retain detect various matric aureus cultur supernat thus result indic bev use produc pure recombin seb natur immunogen properti high yield develop immunodetect assay reliabl sensit routin identif seb various sampl includ food
|
D013211;D001427
|
T123;T007;T116;T131
|
36,290,924
|
cervic imag low resourc set review cervic cancer one signific global health inequ time fourth common cancer women worldwid disproport affect develop countri diseas burden sometim refer prevent cancer progress slowli provid window time routin screen pre cancer lesion identifi treat high mortal rate attribut mani reason includ high cost cytolog base screen lack human resourc conduct screen inadequ prevent medicin servic system due slow progress earli intervent feasibl appropri screen howev standard screen procedur requir access lab base test physician expertis sever imag devic introduc literatur aid cervic screen low resourc set review detail instrument clinic test devic current deploy low resourc locat worldwid devic imag portabl illumin power requir among metric document specif human pilot studi conduct tool
|
D002583
|
T191
|
36,290,923
|
integr power free self contain microfluid chip fiber optic particl plasmon reson aptasensor rapid detect sar cov nucleocapsid protein global pandem covid creat unrival need sensit rapid point care test poct method detect infecti virus novel coronavirus sar cov nucleocapsid protein n protein one abund structur protein virus serv use diagnost marker detect herein report fiber optic particl plasmon reson foppr biosensor employ singl strand dna ssdna aptam recognit element detect sar cov n protein min limit detect lod nm meet accept lod copiesml set target product profil sensor chip microfluid chip base balanc gravit potenti capillari forc control fluid load thus enabl power free auto flow function also risk free self contain design avoid risk virus leak environ find demonstr potenti design low cost robust poct devic toward rapid antigen detect earli screen sar cov relat mutant
|
D000086382;D015374
|
T075;T047;T059;T067
|
36,290,922
|
dielectrophoresi approach increas sensit reduc respons time suppress nonspecif bind biosensor perform receptor base biosensor often limit either diffus analyt caus unreason long assay time lack specif limit sensit due nois nonspecif bind altern current ac electrokinet effect biosens increas field research dedic address issu improv mass transfer analyt electrotherm effect electroosmosi dielectrophoresi dep accord sever work shown improv sensit lower assay time order magnitud thank improv mass transfer techniqu realiz high sensit real sampl realist sampl matrix avoid nonspecif bind critic improv mass transfer ideal specif target analyt paper cover recent approach combin biosensor dep ac kinet approach highest select conclud associ mani challeng sever applic approach could benefici especi work dedic minim nonspecif bind dep offer interest perspect
|
D015374
|
T059;T075
|
36,290,921
|
ruthenium nickel molybd decor porous graphit carbon nitrid high sensit cardiac troponin biosensor two dimension layer materi function monometal bimetal dopant excel materi fabric clinic use biosensor herein report synthesi ruthenium nanoparticl runp nickel molybd nanorod nimoo nrs function porous graphit carbon nitrid pcn fabric sensit select biosensor cardiac troponin ctn wet chemic synthesi rout design synthes pcn runp pcn nimoo nrs morpholog element spectroscop electrochem investig confirm success format materi pcn runp pcn nimoo nrs interfac show signific enhanc electrochem activ surfac area abund site immobil bioreceptor poros excel aptam captur capac pcn runp pcn nimoo nrs materi use develop ctn sensit biosensor show work rang ngml lod pgml pgml respect addit biosensor high select practic applic function pcn materi thus potenti candid develop biosensor detect acut myocardi infract
|
D012428;D006108;D015374
|
T196;T059;T075;T109
|
36,290,920
|
voltammetri peak track longer last refer electrod free electrochem biosensor electrochem aptam base sensor offer reagent free continu analyt measur often suffer poor longev potenti drift even robust electrod system present simpl softwar enabl approach track redox report peak electrochem aptam base sensor use measur redox peak potenti reduc scan window partial measur redox peak height vs baselin x reduct voltag rang measur creat virtual refer standard buffer biofluid blood interstiti fluid therebi elimin effect potenti drift need refer electrod softwar intellig track voltammogram peak potenti via inflect point rise fall slope measur redox peak peak track deriv partial scan valid sever day minim electrochem induc signal loss lt furthermor peak track approach shown robust confound effect foul appli perspect creat wearabl biosensor peak track approach enabl use singl implant work electrod counterrefer electrod may util simpl gel pad electrod surfac skin compar implant work counter refer electrod convent use stabil reliabl also cost invas cumul peak track provid multipl leap forward requir practic molecular monitor extend sensor longev elimin potenti drift simplifi biosensor devic construct vivo placement redox mediat sensor form parabol like data
|
D015374;D052157
|
T059;T075;T114
|
36,290,919
|
smartphon base biosensor non invas monitor total hemoglobin concentr human high accuraci paper propos smartphon base biosensor detect human total hemoglobin concentr vivo high accuraci compar exist biosensor use measur hemoglobin concentr smartphon base sensor util camera memori comput power phone thus cost larg reduc compar exist smartphon base sensor develop high integr multi wavelength led modul special design phone fixtur reduc spatial error motion artifact respect addit embed new algorithm smartphon base sensor improv measur accuraci l b color space transform paramet use perform final quantif collect blood sampl normal anem popul adjust r predict result obtain multipl linear regress method reach rmse reach met accuraci requir non invas detect hemoglobin concentr
|
D000068997;D015374
|
T059;T073;T075
|
36,290,918
|
detect alpha fetoprotein use aptam base sensor alpha fetoprotein afp wide known common use protein biomark liver cancer diagnosi earli stage therefor develop high sensit reliabl method afp detect essenti demand practic applic herein two type aptam base afp detect method ie optic electrochem biosensor review detail optic biosensor includ raman spectroscopi dual polar interferometri reson light scatter fluoresc chemiluminesc electrochem biosensor includ cyclic voltammetri electrochem imped spectroscopi giant magnet imped look futur method afp detect high sensit long term stabil low cost oper conveni continu develop
|
D015374;D052157
|
T059;T075;T114
|
36,290,917
|
fluoresc signal readout crisprca biosensor nucleic acid detect crisprca system use extens nucleic acid detect applic particular tran cleavag activ sever cas effector found crisprca system combin multipl signal readout techniqu develop various molecular diagnost applic fluoresc wide util domin read techniqu crispr biosensor depth understand various fluoresc readout type variabl affect fluoresc signal facilit better experiment design effect improv analyt perform follow two common use type crisprca detect mode first base bind activ cas dcas second base cleavag activ casa casb cas cas review fluoresc signal readout strategi last year base bind activ cleavag activ crisprca system fundament exampl fulli discuss detail comparison avail fluoresc report sequenc design principl summar current challeng applic crispr base detect method discuss accord recent develop
|
D015374;D009696
|
T123;T059;T075;T114
|
36,290,916
|
core shell au tio multi wall carbon nanotub base sensor electroanalyt determin h human blood serum saliva hydrogen peroxid h sensor develop base core shell gold titanium dioxid nanoparticl multi wall carbon nanotub modifi glassi carbon electrod au tio mwcntsgce core shell au tio materi prepar character use scan electron microscopi energi dispers x ray analysi semedx transmiss electron microscopi tem atom forc microscopi afm raman spectroscopi x ray diffract xrd zeta potenti analyz propos sensor au tio mwcntsgce investig electrochem use cyclic voltammetri cv electrochem imped spectroscopi ei analyt perform sensor evalu toward h use differenti puls voltammetri dpv propos sensor exhibit excel stabil sensit linear concentr rang r r limit detect lod achiev physiolog ph condit practic propos sensor test measur h human serum saliva sampl observ respons recoveri result demonstr potenti real world h monitor addit propos sensor detect strategi offer potenti prospect electrochem sensor develop indic oxid stress monitor clinic diagnost general cancer biomark measur paper bleach etc
|
D037742
|
T104;T073
|
36,290,915
|
spectral properti echo tautomer milrinon applic fe ion sens protein stain knowledg spectral properti tautom milrinon mlr solvent solid state well light condit critic import theoret practic point view herein investig spectral properti mlr differ condit use uv vis fluoresc spectroscopi experiment result demonstr mlr undergo tautomer reaction induc solvent polar light ph elicit four tautomer structur enol keto anion cation form interest multi function group mlr enabl coordin metal ion recogn gust molecul h bond use mlr excit state intermolecular proton transfer inter espt fluoresc probe high sensit select analysi fe develop offer sensit detect fe detect limit nm import mlr exhibit abil anchor protein led recognit driven turn inter espt process highlight potenti probe imag protein electrophoresi gel spectral experiment result reveal possibl degrad mechan better understand side effect oral prepar use avail drug inter espt fluoresc probe simpl accur provid good method fe ion sens protein stain
|
D011522;D005456
|
T196;T130
|
36,290,914
|
sensor base carbon nanotub field effect transistor chemic biolog analys nano biochem sensor play import role detect biomark relat human diseas carbon nanotub cnts becom import factor promot vigor develop field due special structur excel electron properti paper focus appli carbon nanotub field effect transistor cnt fet biochem sensor detect biomark first prepar method physic electron properti function modif cnts introduc configur sens mechan cnt fet introduc final latest progress detect nucleic acid protein cell gase ion base cnt fet sensor summar
|
D037742;D009696
|
T104;T123;T073;T114
|
36,290,913
|
label free aptasensor detect fipronil base black phosphorus nanosheet label free fipronil aptasensor built base polylysin black phosphorus nanosheet composit pll bpnss au nanoparticl aunp pll bp modifi glassi carbon electrod gce fabric combin bp nss pll includ consider quantiti nh au nanoparticl aunp place onto gce pll bpnss bond au nps firm assembl thiolat primer ad fix use au bond competit bind fipronil aptam util fipronil quantit assess sensor perform evalu use differenti puls voltammetri dpv method linear equat logc linear correl coeffici r detect limit pgml nm concentr fipronil ngml gml aptasensor appli quantit detect fipronil
|
D052157;D015374;D053768
|
T075;T059;T073;T114
|
36,290,912
|
strong improv sensit phosphoresc base optic oxygen sensor exploit nano porous substrat sensit one crucial factor determin qualiti fluorescencephosphoresc base gas sensor estim measur respons refer measur optic intens sensor absenc presenc analyt molecul various concentr analyt work demonstr phosphoresc base optic oxygen sensor fabric high porous anod aluminum oxid aao membran show dramat high respons sensor exploit enorm surfac area aao facilit effect interact sens molecul analyt spin coat aao membran nm pore diamet platinum base oxygen sens porphyrin dye platinum ii meso tetraki pentafluorophenyl porphyrin pttfpp fabric sensor exhibit oxygen atmospher address general aao membran fabric separ sensor anoth porphyrin dye platinum octaethylporphyrin ptoep exhibit even higher sensor offer highest respons optic oxygen sensor hitherto report sem ed analysi perform realiz effect increas surfac area aao membran enhanc sensit
|
D011166
|
T123;T109
|
36,290,911
|
select specif aptam rivaroxaban util label free electrochem aptasens use gold nanoparticl first announc applic clinic sampl analysi first time novel aptam design util select detect rivaroxaban riv use integr bioinformat biosens technolog select aptam sequenc tag gga aga gaa gga cat atg atg act cac aac tgg acg aac gta ctt atc ccc ccc aat cac tag tga att display high bind affin riv effici abil discrimin riv similar molecular structur novel label free electrochem aptasensor design fabric conjug thiolat aptam au nanoparticl au nps aptasensor success appli quantit determin riv human plasma exhal breath condens ebc sampl limit detect lod nm respect valuabl result provid ampl evid green electrogener aunp surfac electrod interact load aptam base au bind toward sensit select monitor riv human plasma ebc sampl bio assay altern approach clinic analysi riv improv specif affin far know first time electrochem aptasensor verifi recognit riv allow easi fast precis screen riv biolog sampl
|
D052157;D015374;D053768
|
T075;T059;T073;T114
|
36,290,910
|
electr wheelchair manipul system use ssvep base bci system peopl motor disabl use joystick control electr wheelchair howev suffer multipl sclerosi amyotroph later sclerosi may requir method control electr wheelchair studi implement electroencephalographi eeg base brain comput interfac bci system steadi state visual evok potenti ssvep manipul electr wheelchair oper human machin interfac three type ssvep scenario involv real time virtual stimulus display monitor mix realiti mr goggl produc eeg signal canon correl analysi cca use classifi eeg signal correspond class command inform transfer rate itr use determin effect experiment result show propos ssvep stimulus generat eeg signal high classif accuraci cca use control electr wheelchair along specif path simultan local map slam map method avail robot oper softwar ros platform use wheelchair system studi
|
D062207;D014910
|
T074
|
36,290,909
|
electrochem immunosensor determin procalcitonin use gold graphen interdigit electrod procalcitonin pct consid sepsi infect biomark herein interdigit electrochem immunosensor determin pct develop interdigit electrod made laser engrav graphen electrod decor gold legeau nano scan electron microscopi indic legeau nano fabric success anti ptc antibodi immobil surfac electrod use mercaptopropion acid electrochem perform fabric immunosensor studi use electrochem imped spectroscopi ei ei method use determin pct concentr rang pgml limit detect pgml effect sever interf agent c reactiv protein crp immunoglobulin g igg human serum albumin hsa also studi fabric immunosensor good select pct stabil immunosensor also studi month relat standard deviat rsd obtain
|
D006108;D015374;D053768
|
T073;T075;T109;T196;T059
|
36,290,908
|
impact chemosensit outcom brain metastas small cell lung cancer retrospect analysi purpos studi investig prognost differ patient small cell lung cancer sclc differ chemosensit first line chemotherapi develop brain metastasi bm first site progress
|
D055752;D001932;D008175
|
T191
|
36,290,907
|
influenc activ surveil gleason score upgrad prognosi low favor intermedi risk prostat cancer studi focus link activ surveil gleason score upgrad gsu impact prognosi patient prostat cancer pca studi aim analyz effect durat gsu prognost valu base risk stratif elig patient risk stratifi accord aua guidelin low risk lr favor intermedi risk fir unfavor intermedi risk uir pca within surveil epidemiolog end result program seer databas lr fir uir pca patient includ relationship durat gsu identifi univari multivari logist regress discrimin accord risk stratif durat gsu test kaplan meier analysi compet risk regress model proport patient chose highest among lr pca proport uir pca lowest durat associ gsu lr pca high gleason score gs diagnosi strong predictor gsu fir uir pca kaplan meier analysi indic long term surveil made signific differ prognosi uir pca compet risk analysi indic gs upgrad prognosi group signific wors recommend lr fir pca gs upgrad may suitabl uir pca patient
|
D017430;D011471
|
T129;T191;T126;T116
|
36,290,906
|
long term toxic immun checkpoint inhibitor ici melanoma patient ici therapi great improv patient outcom melanoma cost immun relat advers event ira data chronic ira especi real world set current limit perform retrospect chart review adult patient melanoma treat least one cycl ici regimen adjuv metastat set patient receiv pd inhibitor monotherapi receiv dual immunotherapi patient group durat ira perman complet resolut long term resolut period month transient resolut period lt month ira total ira report whole patient popul sixti six patient develop perman ira fifteen experienc long term ira longest last toxic thirti four develop transient ira forti six experienc ira perman ira occur patient treat dual immunotherapi patient treat monotherapi major perman ira endocrin relat skin relat grade perman ira occur patient includ toxic adren insuffici myocard myeliti fifti three patient still requir treatment long term perman ira month follow complet ici therapi includ twenti four patient thyroid hormon replac twenti two oral steroid ici treatment temporarili interrupt ira perman discontinu due ira patient ira patient addit patient die ira find show ici treatment melanoma associ wide rang toxic perman may long last impact patient therefor discuss obtain consent treatment
|
D000074322;D008545
|
T129;T121;T191;T116
|
36,290,905
|
sleep disturb affect immun factor clinic liver cancer patient sleep wake disturb preval patient liver cancer direct evid associ relat biolog mechan studi assess qualiti sleep describ preval sleep disturb patient differ etiolog liver cancer especi explor whether sleep qualiti influenc immun factor
|
D012893;D008113
|
T047;T191;T048
|
36,290,904
|
improv integr palliat radiotherapi support care narrat review palliat radiotherapi prt known effect reliev cancer relat symptom howev mani studi clinic practic show sever barrier hinder use worsen qualiti patient support prt various solut propos overcom barrier train prt support palliat care specialist train palliat care radiat oncologist introduct pathway organiz model specif dedic prt evid innov organiz model mutual train experi spars therefor aim literatur review present quick summari inform avail improv prt qualiti train new pathway innov organiz model major studi integr prt palliat support therapi present low level evid most retrospect analys howev emphas report uniform show advantag come integr prt support therapi activ particip integr prt palliat care provid comprehens support need patient advanc cancer radiat oncologist plan prt also assess manag symptom stress ii rapid refer patient specialist manag complex symptom iii particip multidisciplinari palliat care team end improv educ palliat care resid school profession life continu medic educ clear need particular effect train need radiotherapi resid enabl provid patient comprehens palliat care therefor formal teach adequ durat interact teach method attend palliat care servic educ advanc palliat care plan post graduat school radiotherapi
|
D018787;D009369
|
T191;T091
|
36,290,903
|
pemigatinib intrahepat cholangiocarcinoma work progress cholangiocarcinoma cca second frequent primari liver cancer follow hepatocellular carcinoma hcc progress molecular understand cca led develop sever agent includ fgfr inhibitor pemigatinib whose approv mark new era hepatobiliari malign howev number question remain unansw includ develop secondari resist role combin therapi includ fgfr inhibitor herein specif focus current challeng futur research direct pemigatinib use cca patient
|
D001650;D006528;D008113;D018281
|
T191
|
36,290,902
|
effect radiotherapi pancreat ductal adenocarcinoma patient liver metastas radiotherapi studi treatment local advanc pancreat ductal adenocarcinoma pdac studi analyz effect radiotherapi pdac patient liver metastas studi aim determin whether pdac patient liver metastas improv surviv radiotherapi treatment
|
D021441;D010190;D008113
|
T191
|
36,290,901
|
improv time treatment advanc non small cell lung cancer patient faster singl gene egfr test use idylla egfr test platform patient advanc stage non small cell lung cancer nsclc may benefit short time treatment ttt predict biomark test perform prior treatment recommend various intern expert consensus bodi genet test time intens immunohistochemistri ihc common contribut prolong ttt epiderm growth factor receptor posit patient egfr genet test may requir due mutual exclus action mutat
|
D002289;D008175
|
T191
|
36,290,900
|
f fdg petct petmr patient adren lymphoma systemat review literatur collect case present studi aim assess exist data primari adren lymphoma pal evalu fdg pet describ small monocentr seri case systemat analysi made use pubm web scienc databas report data role fdg petct patient suspici known adren lymphoma qualiti paper assess use quada criteria moreov singl institut collect data patient affect adren lymphoma undergo contrast enhanc comput tomographi cect magnet reson mr fdg petct petmr retriev singular describ seventi eight paper avail pubm web scienc forti seven nr patient studi initi stage diseas n one paper scan made therapi select clinic case relat initi stage diseas restag evalu respons therapi petct petmr alway show high fdg uptak primari adren lesion metastat site moreov pet metric maximum standard uptak valu suvmax metabol tumor volum mtv elev primari adren lesion conclus fdg pet either coupl ct mri use stage restag evalu treatment respons patient affect pal
|
D019788;D008223
|
T191;T130;T109
|
36,290,899
|
boron neutron captur therapi clinic applic research progress boron neutron captur therapi bnct binari modal use treat varieti malign use neutron irradi boron b nuclei enter tumor cell produc high linear energi transfer let alpha particl recoil li nuclei b n li therefor import part bnct select deliv larg number b tumor cell small amount normal tissu far bnct use case worldwid efficaci bnct treatment head neck cancer malign meningioma melanoma hepatocellular carcinoma confirm collect collat clinic studi second generat boron deliveri agent combin differ drug mode administr combin multipl treatment import impact patient surviv summar critic issu must address hope next generat boron deliveri agent overcom challeng
|
D016754;D001932;D008545;D006258
|
T061;T191
|
36,290,898
|
stereotact bodi radiat therapi lung liver oligometastas breast cancer toxic data prospect non random phase ii trial report matur toxic data phase ii non random trial use sbrt lung liver oligometastas
|
D016634;D001943;D008113
|
T061;T191
|
36,290,897
|
complic risk factor en bloc resect spinal tumor retrospect analysi patient treat singl institut en bloc resect consist surgic remov vertebr tumor singl piec suffici margin improv surviv reduc recurr rate procedur technic demand correl high complic rate purpos studi investig risk factor complic en bloc resect evalu benefit overcom risk term overal surviv retrospect analyz prospect collect data patient treat en bloc resect complic classifi accord save v overal surviv estim use kaplan meier method total patient suffer least one complic moreov advers event collect intraop earli post oper late post oper classifi grade sever scale ten year overal surviv ci occurr relaps associ increas risk mortal ci complic affect overal surviv despit high complic rate en bloc resect allow better control diseas perform select patient special surgeon
|
D013125
|
T191
|
36,290,896
|
outcom high dose stereotact ablat radiotherapi allmultipl site oligometastat renal cell cancer patient stereotact ablat bodi radiotherapi sabr one treatment option oligometastat renal cell carcinoma rcc limit lack data evalu high dose sabr allmultipl site
|
D002292;D016634;D007680
|
T061;T191
|
36,290,895
|
therapeut advanc rare alk fusion non small cell lung cancer non small cell lung cancer nsclc account approxim lung cancer case lead caus cancer relat death despit advanc chemotherapi immunotherapi prognosi advanc patient remain poor discoveri oncogen driver mutat anaplast lymphoma kinas alk mutat mean subset patient opportun target therapi improv genet test coverag alk fusion subtyp alk partner discov rare alk fusion subtyp found nsclc howev unlik common fusion echinoderm microtubul associ protein like eml alk rare alk fusion striatin strn alk huntingtin interact protein hip alk etc larg scale clinic data relat efficaci still immatur clinic applic alk tyrosin kinas inhibitor alk tkis main depend posit alk gene regardless molecular characterist fusion partner recent clinic studi alk posit nsclc popul demonstr differ progress free surviv pfs among patient base differ alk fusion subtyp articl introduc biolog characterist alk fusion kinas common detect method alk fusion focus summar differenti respons sever rare alk fusion alk tkis propos correspond treatment strategi better guid applic alk tkis rare alk fusion popul
|
D002289;D008175
|
T191
|
36,290,894
|
lymphadenectomi benefit small cell carcinoma ovari popul base analysi small cell carcinoma ovari scco rare type ovarian cancer high aggress optim treatment modal remain elus studi aim comprehens investig surviv impact clinic characterist treatment includ lymphadenectomi scco retrospect cohort studi perform includ patient surveil epidemiolog end result seer databas data collect includ demograph therapeut detail patholog characterist propens score match analysi psm carri balanc baselin variabl scco non scco cox regress kaplan meier stratifi analys conduct psm filter record scco record non ssco obtain patient scco prone present unilater tumor p lt larger tumor size gt cm cm vs p lt younger age vs p lt singl status vs p lt singl malign tumor lifetim vs p patholog grade iv diseas vs p lt compar non scco balanc baselin clinic characterist ratio psm total match patient scco patient non scco identifi surviv rate scco distinct inferior non scco particular figo ii iii stage lymphadenectomi perform scco patient found patholog posit lymph node lymphadenectomi link favor overal surviv scco particular advanc stage also independ prognost factor wherea lymphadenectomi reveal edg match non scco pronounc surviv benefit scco least node resect lymphadenectomi non stage depend way consid deserv clinic valid promot overal surviv scco
|
D018288;D055752;D008175
|
T191
|
36,290,893
|
promis immun treatment advanc cutan squamous cell carcinoma cemiplimab real world experi global sar cov pandem cutan squamous cell carcinoma cscc second frequent non melanoma skin cancer standard curat treatment surgic resect treatment local advanc metastat diseas apart radiotherapi current base cemiplimab cemiplimab demonstr efficaci treatment advanc metastat cscc clinic trial although real world data still limit present four case cscc show tremend respons cemiplimab one patient achiev complet respons three achiev partial respons immunotherapi cemiplimab recent approv pd inhibitor import addit cutan oncolog therapeut option may consid patient advanc diseas amen surgeri radiotherapi four case patient postpon visit doctor fear sar cov infect administr organiz reason declar difficult access doctor caus pandem
|
D002294;D012878;D000074322;D000086382
|
T121;T129;T116;T067;T191;T047
|
36,290,892
|
mind base stress reduct influenc qualiti life anxieti depress women diagnos breast cancer review breast cancer common form cancer diseas worldwid treatment lead varieti physiolog psycholog side effect review investig question mind base stress reduct mbsr stress manag program influenc qualiti life anxieti depress women diagnos breast cancer
|
D064866;D001943
|
T191;T041
|
36,290,891
|
health behavior cancer prevent among adult li fraumeni syndrom relat germani cohort descript li fraumeni syndrom lfs rare high penetr cancer predisposit syndrom cps caus pathogen variant pvs tp physic activ pa mediterranean diet lead cancer reduct surviv benefit increas qualiti life qol yet unstudi among lfs tp pv carrier pvc relat question dietari pattern mediterranean diet adher screener pa freiburg questionnair qol short form health survey smoke alcohol consumpt percept cancer risk german bi centric studi march june studi enrol pvc relat women compar men vs p pvc relat vs p show healthier diet associ particip surveil p educ diet p smoke p women smoke less vs packyear p psycholog well higher among men sf male vs femal p pvc rate cancer risk statist higher relat vs p lt howev cancer risk general popul rate lower vs p lt relat cancer relat death increas estim person cancer risk p possibl reduc cancer self determin health behavior among pvc relat yet exhaust educ famili cps cancer prevent behavior requir investig regard accept real life implement
|
D016864
|
T047
|
36,290,890
|
effect exercis intervent gait function young survivor osteosarcoma megaendoprosthesi lower extrem result pilot random control trial progait limb preserv megaendoprosthesi adolesc young adult aya bone tumor associ function limit gait abnorm progait trial evalu effect exercis program gait function qualiti life function scale msts tess function mobil fatigu secondari outcom eleven aya survivor malign osteosarcoma tumor endoprosthesi around knee mean age year random intervent group receiv week exercis program control group gait function assess via motion captur analyz use gait profil score gps gait deviat index gdi gdi gps score particip suggest deviat healthi refer group exercis intervent small medium posit effect gait score gdi unaffect leg affect leg subject function score tess msts function test tug tud none chang show statist signific promis intervent effect suggest regular exercis could improv lower limb function follow care survivor howev power rct follow project need confirm pilot find
|
D012516;D001859
|
T191
|
36,290,889
|
geriatr g score associ surviv outcom older patient advanc prostat cancer adher prospect studi meet uro network introduct androgen receptor pathway inhibitor arpi increas offer older patient prostat cancer pc howev prognost factor relev outcom arpi still littl investig method materi meet uro network adher prospect multicentr observ cohort studi evalu monitor adher arpi metastat castrat resist pc mcrpc patient age cox regress univari multivari analys radiograph progress free rpfs overal surviv os perform unsupervis median valu literatur base threshold avail use cut off quantit variabl result overal patient enrol median age year treat abirateron abi enzalutamid enz median follow month mo median rpfs mo ci os mo ci mva independ prognost factor wors rpfs os geriatr g assess p lt p psa declin p lt time castrat resist mo set treatment ie post abienz rpfs p lt p respect age year os p conclus baselin g screen recommend mcrpc patient age optimis arpi vulner individu includ earli introduct palliat care
|
D064129
|
T191
|
36,290,888
|
cancer patient first treat chemotherapi like receiv surgeri pandem due ramp cancer surgeri earli pandem mani newli diagnos patient receiv treatment first aim quantifi pandem relat shift rate surgeri follow chemotherapi retrospect popul base cohort studi involv adult diagnos cancer januari novemb ontario canada receiv chemotherapi first treatment within month diagnosi compet risk regress model interact effect use quantifi associ covid period receiv cancer diagnosi onaft march receipt surgic resect month first chemotherapi among patient n ultim underw surgeri month chemotherapi initi receipt surgeri higher pandem shr ci materi depriv independ associ lower receipt surgeri least vs depriv quintil shr ci chang pandem surgic rate increas pronounc breast cancer shr ci pandem relat shift cancer treatment requir evalu understand long term consequ persist materi depriv relat inequ cancer surgic access need address
|
D000086382;D001943
|
T047;T191;T067
|
36,290,887
|
rational efficaci safeti evid lenvatinib pembrolizumab associ anaplast thyroid carcinoma anaplast thyroid carcinoma atc high aggress malign tumor poor overal prognosi despit multimod therapi atc extrem rare random control studi publish metastat diseas thyrosin kinas inhibitor especi lenvatinib immun checkpoint inhibitor pembrolizumab emerg drug atc studi report efficac pembrolizumab lenvatinib associ result frequent label use review discuss rational efficaci safeti evid associ lenvatinib pembrolizumab atc first discuss preclin rational pembrolizumab monotherapi lenvatinib monotherapi synergist action pembrolizumab lenvatinib metastat set also discuss clinic evid immunotherapi pembrolizumab atc analysi studi evalu immunotherapi lenvatinib pembrolizumab lenvatinib associ atc addit discuss safeti associ potenti predict biomark effici
|
D065646;D013964
|
T191
|
36,290,886
|
clinic manag financi toxic identifi opportun experienti insight cancer survivor caregiv social worker perspect cancer survivor caregiv social worker key stakehold clinic manag financi toxic ft critic identifi opportun better ft manag semi structur interview cancer survivor caregiv focus group social worker undertaken use purpos sampl quaternari public hospit australia peopl cancer diagnosi attend hospit elig data analys use induct deduct content analysi techniqu twenti two stakehold n cancer survivor mix cancer type n caregiv n social worker particip key find includ genuin concern ft cancer survivor caregiv shown practic support health care social worker ii need clariti role servic iii import time inform flow iv proactiv navig prioriti cancer survivor caregiv receiv financi assist support hospit lack synchronis share understand role servic relat financ cancer survivor caregiv health profession undermin effect consist servic proactiv approach anticip cancer survivor caregiv need recommend futur research may develop evalu initi manag cancer survivor famili ft experi outcom
|
D000073116;D009369
|
T201;T191;T101
|
36,290,885
|
clinic factor associ long term surviv metastat melanoma treat anti pd alon combin ipilimumab immun checkpoint inhibitor ici treatment metastat melanoma mm offer last overal surviv os benefit subset patient howev outcom remain poor non respond clinic predictor long term surviv remain elus util alberta immunotherapi databas investig associ host diseas characterist treatment factor overal surviv os greater year identifi patient treat august may singl agent anti pd combin anti pd anti ctla ici regimen logist regress model use assess independ associ clinic factor captur surviv greater year statist signific factor univari analysi assess use multivari analysi total patient identifi short term lt year long term gt year surviv surviv lt year surviv gt year median age patient ecog logist regress breslow depth mm normal serum ldh normal serum albumin stage ab associ os gt year univari multivari analysi ecog lt dnlr normal hemoglobin associ surviv univari analysi multivari analysi object respons rate long term survivor compar short term survivor studi identifi four easili access predictor long term surviv larg real world mm cohort treat ici
|
D000074322;D008545;D016609
|
T129;T121;T191;T116
|
36,290,884
|
singl cell transcriptom endotheli cell upper lower human esophag squamous cell carcinoma esophag squamous cell carcinoma escc type progress distant metastat tumor target anti angiogen gene could effect hinder escc develop metastasi wherea escc locat upper lower esophagus show differ respons clinic treatment suggest escc locat taken account explor new therapeut target current studi find novel anti angiogen therapeut target identifi endotheli cell subset upper lower human escc use singl cell rna sequenc scrna seq screen differenti express gene deg perform gene ontolog go kyoto encyclopedia gene genom kegg analysi result show common deg share upper lower endotheli cell main involv vessel develop angiogenesi cell motil endotheli cell regul pik akt rap ras tgf beta apelin signal pathway critic regulatori gene identifi itgb cola cola itga lama lamb lamc vwf itga thbs pdgfb pgf rhoc ctnnb cell metabol relev gene eg mgst pnp upp hyal might prospect therapeut target furthermor found deg upper endotheli cell mapk stat rhoa mapk hifa fgfr gng gnb arhgef main regul cell adhes structur morphogenesi motil phospholipas apelin vegf signal pathway moreov deg lower endotheli cell instanc plcg efna calm rala main regul cell apoptosi surviv target calcium ion transport rap ras camp phospholipas phosphatidylinositol signal pathway addit upper endotheli cell show signific function divers cytokin respons migratori prolif capac present better angiogen capac make sensit anti angiogen therapi compar lower endotheli cell studi identifi potenti target gene anti angiogen therapi upper lower escc indic anti angiogen therapi might effect upper escc still need examin futur
|
D000077277;D004938;D010739
|
T191;T126;T116
|
36,290,883
|
outcom earli transit low risk thyroid cancer patient specialist primari care recent publish clinic pathway manag thyroid cancer outlin criteria transit low risk patient primari care within one five year diagnosi howev discharg pattern among endocrinologist remain heterogen lack consensus regard post treatment care thyroid cancer patient
|
D013954;D013964
|
T125;T121;T191;T116
|
36,290,882
|
siglec new perspect therapi target human giant cell tumor bone main featur giant cell tumor bone gctb frequent recurr aggress osteolysi lead poor prognosi patient although treatment method gctb scrape resect effect inhibit diseas tendenc toward malign transform remain therefor import identifi new treatment method gctb studi first found high siglec express gctb tissu signific associ campanacci stage tumor recurr spearman analysi siglec express signific correl ki level tumor tissu vitro mrna protein level siglec high gctb stromal cell hs siglec knockdown inhibit biolog characterist gctb stromal cell rna sequenc result enabl predict downstream gene use kyoto encyclopedia gene genom kegg gene ontolog go mcode analys find show cxcl signific regul siglec might promis downstream target gene siglec therefor siglec may potenti immunotherapi target gctb
|
D018212;D001859
|
T191
|
36,290,881
|
postop patient report outcom uniport video assist thoracoscop surgeri use periop symptom assess lung surgeri scale studi aim use new special inventori lung surgeri patient evalu postop symptom function status identifi factor may affect uniport video assist thoracoscop surgeri vat singl center longitudin cohort observ studi use new scale periop symptom assess lung surgeri psa lung evalu recoveri symptom function status patient undergo uniport vat divid patient two group accord patient symptom score compar clinic characterist two group item conduct qualit interview regard cough postop week exact patient enrol studi two highest score patient report outcom pro item short breath cough fourth week surgeri thirti one patient report cough sever influenc live postop week use psa lung inventori found short breath worst symptom postop week although cough import symptom earli postop period affect patient live postop week therefor research requir determin optim cut point cough
|
D020775;D008175
|
T061;T191
|
36,290,880
|
plasmacyt pleural effus major present angioimmunoblast cell lymphoma case report angioimmunoblast cell lymphoma one peripher cell lymphoma reactiv plasma cell occasion observ aitl patient peripher blood bone marrow plasmacyt pleural effus present aitl report mechan plasmacyt pleural effus fulli understood present year old male exuber plasma cell pleural effus addit peripher blood bone marrow aspir present case would like expand spectrum diseas present aitl discuss signific flow cytometri differenti diagnosi pleural effus knowledg first case report literatur crucial assist hematopathologist accur diagnosi treatment
|
D007119;D016411;D010996
|
T047;T191
|
36,290,879
|
apprais health technolog assess agenc econom evalu submit part reimburs dossier oncolog treatment evid canada uk australia public fund healthcar system includ canada unit kingdom uk australia often use health technolog assess hta inform drug reimburs decis make base dossier submit manufactur hta agenc issu public avail report support fund recommend howev level inform report hta agenc report may vari provid insight issu describ assess report econom method recent oncolog hta recommend canadian agenc drug technolog health cadth nation institut health care excel nice pharmaceut benefit advisori committe pbac public avail hta recommend report oncolog drug issu cadth year period identifi compar correspond hta document nice pbac report key model characterist attribut surviv analysi method methodolog critic assess econom result character use descript statist dichotom differ methodolog critic observ three agenc assess use cochran q test substanti use pairwis mcnemar test chi squar test use assess dichotom differ report method explor potenti relationship categor variabl appropri htas publish cadth nice pbac consist report broad spectrum descript inform econom model submit manufactur common econom evalu attribut well report across three hta agenc signific differ report surviv analysi method methodolog critic observ nice consist report comprehens inform compar either cadth pbac despit differ broad similar recommend rate observ cadth nice pbac found restrict base year sampl oncolog htas publish cadth match correspond htas nice pbac observ import variat report econom evid especi technic aspect surviv analysi across three agenc addit guidelin hta submiss manufactur communiti hta agenc also common standard report result assess though inform opinion report may differ
|
D013673
|
T058
|
36,290,878
|
manag prognosi patient recurr persistentprogress uterin carcinosarcoma uterin carcinosarcoma uc high aggress gynecolog malign recurr persistentprogress diseas usual fatal aim investig manag prognosi patient clinic record uc patient june april retrospect review stage assign figo stage system univari multivari analys use identifi independ predictor surviv recurr sar cancer specif surviv css patient experienc treatment failur median time treatment failur ttf month rang median follow time censor patient month rang year sar rate recurr persistentprogress diseas multivari analysi salvag therapi main use radiotherapi hr ci chemotherapi hr ci chemoradiotherapi crt hr ci associ improv sar wherea dissemin recurr associ signific wors sar hr ci p salvag therapi use radiotherapi chemotherapi crt signific improv sar surgeri signific improv css sar adjust confound factor
|
D002296;D014594
|
T191
|
36,290,877
|
predictor function recoveri among musculoskelet oncolog patient undergo lower extrem endoprosthet reconstruct function outcom import oncolog patient undergo lower extrem reconstruct object current studi describ patient report function surgeri identifi predictor postop function musculoskelet oncolog patient undergo lower extrem endoprosthet reconstruct
|
D012983;D012509;D005870
|
T191
|
36,290,876
|
understand treatment pattern outcom among patient de novo unresect local advanc metastat urotheli cancer popul level retrospect analysi alberta canada despit high diseas burden real world data treatment pattern patient unresect local advanc metastat urotheli carcinoma lamuc canada limit retrospect longitudin cohort studi describ treatment pattern surviv popul patient de novo unresect lamuc alberta canada diagnos januari decemb follow mid outcom interest system therapi treatment pattern overal surviv os patient n receiv system therapi patient receiv first line system therapi median durat treatment month iqr thirti five patient receiv first line therapi receiv subsequ second line therapi median month iqr patient n median os diagnosi month ci patient receiv treatment median os initi first line second line system therapi month respect major patient receiv first line system therapi surviv outcom poor studi highlight signific unmet need safe efficaci therapi patient lamuc canada
|
D002295;D001749
|
T191
|
36,290,875
|
access cancer drug canada lung cancer multipl subtyp identifi myriad new effect therapi provid fertil ground highlight issu relat oncolog drug access canada
|
D000970;D008175
|
T121;T191;T109
|
36,290,874
|
mediterranean diet support intervent cancer patient current evid futur direct cancer current repres lead caus morbid mortal held respons one six death worldwid
|
D038441;D009369
|
T061;T191
|
36,290,873
|
predict signific prognost nutrit index serum albuminglobulin ratio overal surviv penil cancer patient undergo penectomi object assess valu use prognost nutrit index pni serum albuminglobulin ratio agr predict overal surviv os patient penil cancer pc undergo penectomi materi method retrospect analysi patient admit hospit due pc april septemb underw penectomi includ studi optim cut valu pni agr determin receiv oper characterist curv analysi kaplan meier analysi cox proport hazard model use evalu correl pni agr os patient pc result total patient die follow period median follow time month best cut valu pni agr set confid interv youden index sensit specif p lt confid interv youden index sensit specif p kaplan meier analysi show os patient high pni group high agr group signific higher patient low pni group low agr group p lt univari analysi show acci clinic n stage patholog stage pni agr sii plr predictor os patient pc p lt multivari analysi show pni risk rate hr ci p agr risk rate hr ci p independ prognost factor predict os patient pc undergo penectomi conclus pni score serum agr independ prognost factor predict os patient pc undergo penectomi
|
D010412;D005916
|
T123;T191;T116
|
36,290,872
|
papillari tumor pineal region rare pediatr cns tumor case seri treat king fahad medic citi kfmc clinic behavior prognosi appropri treatment papillari tumor pineal region ptpr fulli defin due rariti tumor diagnosi ptpr may present clinic symptom includ headach obstruct hydrocephalus diplopia vomit lethargi well neurolog sign includ argyl robertson pupil parinaud syndrom due compress dorsal midbrain specif periaqueduct region horizont nystagmus radiolog assess pineal region lesion challeng wide rang potenti differenti diagnos ptpr typic present heterogen well circumscrib mass pineal region might contain cystic area calcif hemorrhag protein accumul report three femal pediatr patient ptpr treat king fahad medic citi kfmc saudi arabia histolog immunohistochem diagnosi confirm analysi genom wide dna methyl profil case seri expand avail report clinic present ptpr provid import inform respons differ treatment modal
|
D010871;D001932;D010870
|
T023;T191
|
36,290,871
|
repurpos effect lu dotat treatment mantl cell lymphoma mantl cell lymphoma mcl uncommon subcategori non hodgkin lymphoma nhl pathogenesi primarili includ overexpress ccnd sox along molecular aberr lutetium lu dotat radiolabel somatostatin analogu use treatment gastrointestin neuroendocrin tumor clinic data support use lutetium lu dotat treatment lymphoma describ case year old man histori mcl carcinoid tumor lung follow progress carcinoid malign patient treat lutetium lu dotat treatment overal improv patient mcl demonstr stabl lymphadenopathi serial ct scan trend absolut lymphocyt count therefor hypothes lu dotat might role repurpos treat mcl
|
D020522;D002276
|
T047;T191
|
36,290,870
|
hepatocellular carcinoma alpha fetoprotein liver alloc transplant past present futur hepatocellular carcinoma hcc one lead indic liver transplant treatment choic due oncolog benefit patient advanc chronic liver diseas advcld small tumor last year hcc patient undergo liver transplant alpha fetoprotein afp increas appli independ predictor overal surviv diseas free recurr waitlist drop addit static afp newer studi evalu afp dynam respons downstag therapi show enhanc prognost compar static afp alon afp util select hcc patient transplant despit year alloc polici chang us alloc system continu take uniform approach hcc patient without discrimin favor unfavor tumor biolog aim review histori liver alloc hcc us util afp liver transplant implic weav afp biomark polici base review encourag us transplant communiti revisit hcc organ alloc model incorpor precis oncolog principl patient select adopt afp dynam better stratifi waitlist dropout risk
|
D006528;D016031;D008113
|
T061;T191
|
36,290,869
|
venetoclax combin azacitidin treatment newli diagnos acut myeloid leukemia canadian cost util analysi treatment acut myeloid leukemia aml typic involv intens chemotherapi ic howev unmet need approxim aml patient deem unfit inelig ic purpos studi evalu canadian perspect econom impact venetoclax combin azacitidin venaza treatment patient newli diagnos aml year older comorbid preclud use ic lifetim partit surviv model develop assess cost effect venaza compar aza health state includ event free surviv progressiverelaps diseas death efficaci paramet base vial trial analys conduct ministri health moh societ perspect lifetim horizon venaza associ gain qualiti adjust life year qali compar aza moh perspect venaza aza associ total cost respect result increment cost util ratio qali result similar societ perspect econom evalu demonstr comparison aza venaza cost effect strategi treatment patient newli diagnos aml deem unfit ic
|
D001374;D015470
|
T121;T191;T114
|
36,290,868
|
peripher blood cell ratio prognost indic neoadjuv chemotherapi treat breast cancer cohort breast cancer repres heterogen condit interact host immun respons primari oncogen event impact diseas progress ratio system blood base immunocyt emerg clinic relev prognost biomark cancer patient nlr neutrophil lymphocyt ratio shown prognost varieti cancer includ breast cancer howev evalu prognost valu overal surviv os diseas free surviv dfs key immunocyt ratio neutrophil lymphocyt ratio nlr lymphocyt monocyt ratio lmr neutrophil white cell count ratio nwr lymphocyt white cell count ratio lwr monocyt white cell count ratio mwr platelet lymphocyt plr breast cancer subtyp neoadjuv chemotherapi nac cohort remain fulli explor nac treat breast cancer cohort compris lumin lumin b posit tripl negativebas breast cancer treat tertiari referr center minimum year follow use calcul immunocyt ratio immunocyt cut valu calcul gt specif use decis tree model associ subtyp specif os dfs tumor grade analyz use cut off calcul use receiv oper characterist curv decis tree model decis tree calcul ratio show lmr mwr signific associ lumin os p p dfs p p lumin b os p p dfs p p nlr lwr signific associ posit os p p nlr nwr signific associ dfs p p signific associ observ immunocyt ratio tripl negat cohort result demonstr subtyp specif prognost valu immunocyt ratio nac treat breast cancer patient valid immunocyt ratio provid clinician new prognost aid diseas manag monitor
|
D020360;D064726
|
T061;T191
|
36,290,867
|
classif brain tumor magnet reson imag use vision transform ensembl autom classif brain tumor play import role support radiologist decis make recent vision transform vit base deep neural network architectur gain attent comput vision research domain owe tremend success transform model natur languag process henc studi abil ensembl standard vit model diagnosi brain tumor weight tw magnet reson imag mri investig pretrain finetun vit model b b l l imagenet adopt classif task brain tumor dataset figshar consist tw contrast enhanc ce mri slice meningioma glioma pituitari tumor use cross valid test ensembl vit model abil perform three class classif task best individu model l overal test accuraci resolut ensembl four vit model demonstr overal test accuraci resolut outperform individu model abil resolut ensembl resolut conclus ensembl vit model could deploy comput aid diagnosi brain tumor base tw ce mri lead radiologist relief
|
D001932;D005910
|
T191
|
36,290,866
|
adher mediterranean diet nutrit status women breast cancer impact diseas progress recurr free patient surviv introduct nutrit status impact surviv patient cancer studi investig role nutrit status breast cancer surviv women breast cancer even fewer regard impact adher mediterranean diet md present studi aim assess nutrit status md adher physic activ level health relat qualiti life hrqol women diagnos breast cancer evalu paramet regard recurr free surviv method total women age year old diagnos breast cancer larissa greec particip studi tumor histopatholog report anthropometr indic measur train nurs questionnair regard nutrit status via mini nutrit assess hrqol via eortc qlq c physic activ level via ipaq mediterranean diet adher via meddietscor administ particip follow maximum time interv month recurr occur result total patient overweight obes women undernourish risk malnutrit month follow patient relaps median time recurr month iqr month rang month higher level md adher signific associ lower bodi mass index bmi valu earlier diseas stage smaller tumor size absenc lymph node metastas better physic activ level p lt normal nutrit status signific associ higher bmi valu better health relat qualiti life p univari analysi patient higher level md adher well nourish patient signific longer recurr free surviv p lt multivari analysi md adher nutrit status independ associ recurr free patient surviv adjust sever confound factor p lt conclus impact md time recurr still investig futur intervent studi need focus role adher md therapi surviv breast cancer progress furthermor present studi also highlight import adequ nutrit status diseas progress need nutrit assess educ intervent women breast cancer
|
D038441;D001943
|
T061;T191
|
36,290,865
|
time trend upper gastrointestin cancer incid china analysi use age period cohort model aim studi investig upper gastrointestin cancer incid trend china joinpoint softwar evalu age effect cohort effect period effect use age period cohort model data obtain global burden diseas injuri risk factor studi crude incid rate cr upper gastrointestin cancer china increas averag annual percent chang aapc p lt age standard incid rate asir decreas aapc p lt net drift p lt local drift age group male age group femal less p lt age effect show upper gastrointestin cancer onset risk gradual increas age period effect fundament manifest downward trend onset risk cohort effect indic decreas onset risk overal birth cohort asir upper gastrointestin cancer china show downward trend onset risk indic age period cohort effect
|
D005770
|
T191
|
36,290,864
|
neuroendocrin carcinoma uterin cervix endometrium ovari show higher tendenc bone brain liver organotroph metastas neuroendocrin carcinoma nec femal genit tract rare aggress subtyp cancer still poor understood sever recent studi report pulmonari gastroenteropancreat neuroendocrin neoplasm show signific differ pattern metastasi compar non nec primari site aim studi evalu metastat pattern gynecolog nec compar metastat pattern nec non nec primari site retriev analyz cervic endometri ovarian nec case surveil epidemiolog end result seer databas valid result also retriev analyz cervic nec case institut databas uterin cervic nec common nec overal metastat rate signific higher nec group non nec group three primari site cervic endometri ovarian nec show higher tendenc bone brain liver organotroph metastasi non nec primari site demonstr gynecolog nec show signific differ metastat pattern compar non nec primari site find might help clinician better manag patient gynecolog nec
|
D002583;D018278;D018358;D008113
|
T191
|
36,290,863
|
neoadjuv chemo radiat use igrt patient local advanc gastric cancer goal studi see effect safe neoadjuv chemoradi imag guid imrt patient local advanc resect gastric cancer januari june patient local advanc ctct n gastric cancer treat neoadjuv chemoradiotherapi pumch peke union medic colleg hospit retrospect studi use concurr chemotherapi capecitabin alon xelox cycl radiotherapi imrt intens modul radiat therapi gy week deliv igrt imag guid radiotherapi start week therapi ensur accuraci repeat total patient enrol studi stage ctt stage n patient tumor locat upper stomach patient complet neoadjuv chemoradi patient undergo stomach resect gastrostomi patholog downstag found patient patient receiv downstag patient receiv n downstag individu patholog complet respons pcr averag period follow month month year os overal surviv lrfs local recurr free surviv dmfs distant metastasi free surviv rate patient ci ci ci respect thirteen patient grade leukopenia anemia thrombocytopenia patient grade anemia patient grade thrombocytopenia pcr found signific predict factor os multivari analysi hr ci p method use igrt imag guid imrt gy fraction week combin concurr chemotherapi patient local advanc resect gastric cancer equal effect compar clinic efficaci neoadjuv chemoradiotherapi clinic outcom achiev equal efficaci similar pcr rate high rate os lrfs dmfs well good toler concurr chemoradiotherapi accept side effect
|
D013274;D061089;D013921;D000740
|
T061;T047;T191
|
36,290,862
|
small bowel adenocarcinoma year experi cancer center ottawa hospit toh background small bowel adenocarcinoma sba one predomin primari small bowel cancer dismal outcom aim report year experi sba manag region cancer centr canada method retrospect analys clinic patholog data patient diagnos sba ottawa hospit toh ottawa canada describ clinicopatholog featur outcom includ surviv potenti prognost factor analys use cox proport hazard model multivari analysi result identifi patient sba duodenum common sba locat repres total patient follow jejunum ileum around case present bowel obstruct major patient stage iv diseas present seven patient msi high tumour ms stabl term manag patient underw curat surgic resect receiv adjuv chemotherapi hand patient advanc diseas receiv palliat system therapi patient support care median follow month rang median overal surviv month stage ii iii iv respect p lt median recurr free surviv month stage ii iii respect howev statist signific differ tnm stage rfs p multivari cox regress analysi show poor perform status diagnosi predictor shorter overal surviv p lt univari analysi nt show signific correl rfs covari conclus sba remain one aggress tumour dismal prognosi even surgic resect optim chemotherapi regimen establish studi need explor role adjuv chemotherapi stage iii sba
|
D007414;D000230
|
T191
|
36,290,861
|
dispar caus mortal older patient colorect cancer accord disabl status nationwid analysi although investig pattern cancer mortal import understand effect cancer popul health knowledg regard mortal cancer patient disabl scarc studi examin associ disabl status caus mortal older patient colorect cancer
|
D015179
|
T191
|
36,290,860
|
acut metastat spinal cord compress urgent surgeri versus radiotherapi treatment result predict versus actual result background context role radiotherapi versus surgeri treat acut metastat spinal cord compress amscc chang year purpos studi evalu neurolog function outcom follow urgent surgeri radiotherapi usfr versus urgent radiotherapi alon treat amscc studi designset retrospect cohort patient amscc variabl neurolog deficit overal patient treat usfr receiv urgent radiotherapi alon outcom measur neurolog status regard asia frankel score contin ambul kranofski function score patient life span compris outcom measur method retrospect emr studi result usfr radiotherapi cohort similar age gender tumor origin number spinal metastas common caus amscc carcinoma breast follow carcinoma lung multipl myeloma neurolog status amscc present similar cohort regard asia frankel score contin ambul kranofski function score follow usfr patient motor strength improv regain sphincter function regain ambul patient treat radiotherapi show improv one patient radiotherapi lost sphincter function treatment receiv affect patient surviv subanalysi patient short life expect tomita tokuhashi score show miss predict case conclus studi support benefici effect ufsr compar urgent radiotherapi alon treat amscc subgroup earli surgeri improv function motor strength sphincter control ambul without affect life span prognost score fail predict life span almost one third patient requir investig
|
D013117;D013125;D002277
|
T047;T191
|
36,290,859
|
tp mutat map advanc non small cell lung cancer real world retrospect cohort studi tp frequent mutat solid tumor basic mutat map mix particular aggress stage lung cancer
|
D002289;D008175
|
T191
|
36,290,858
|
wide dissect tran sulcal approach resect deep intra axial lesion eloqu brain area introduct resect intra axial tumor iat eloqu brain region risk major postop neurolog deficit awak craniotomi often use navig area howev patient inelig awak procedur tran sulcal approach tscal introduc reduc parenchym trauma tumor resect report experi util tscal resect deep iat locat eloqu area materi method singl center retrospect analysi patient underw iat resect eloqu area via tscal januari april seventeen case review relev data collect fluoresc guid surgeri aminolevulin acid ala intraop ultrasound perform case result seventeen patient male femal averag year old rang includ studi averag length stay day patient requir hospit readmiss within day gross total resect gtr achiev patient subtot resect occur patient eleven patient report full resolut symptom patient report deficit improv patient experienc chang preoper deficit patient develop new perman deficit postop discuss gtr preoper deficit reduct complic compar awak craniotomi tscal studi ancillari intraop techniqu brain map ala intraop ultrasound afford tscal improv resect rate overal outcom conclus tscal option patient deep lesion eloqu area candid awak surgeri
|
D000622;D001932
|
T123;T121;T116;T109;T191
|
36,290,857
|
immunotherapi radiotherapi antitumor long rang weapon partnership unsolv challeng dose fraction volum therapeut sequenc immunotherapi modern oncolog treatment immun checkpoint inhibitor ici part clinic practic malign melanoma decad anti cytotox lymphocyt antigen ctla anti program cell death protein pd anti program death ligand pd l agent current part therapeut arsenal metastat relaps diseas numer cancer recent also evalu valid consolid therapi advanc local stage combin radiotherapi treatment histor consid loco region chang paradigm offer via synergist effect potenti increas immun mediat tumor destruct howev fragil balanc tumoricid effect immun mechan immunosuppress induc radiotherapi mean absenc ici immun mediat potenti effect radiotherapi distanc site administr rare analysi preclin clinic data especi evid pacif clinic trial consid hypofraction irradi reduct irradi volum order protect immun infiltr tumor microenviron perform concurr immunotherapi maximum week start ici treatment could bring maximum benefit addit avoid radiat induc lymphopenia rild protect anatom lymphoid structur larg blood vessel well use irradi partial tumor volum even plurimetastat diseas convers cold immunolog tumor hot immunolog tumor modern concept radiotherapi era immunotherapi low dose radiotherapi could also propos plurimetastat case effect differ model tme high dose per fraction irradi cell death releas antigen facilit immun mediat cell death
|
D061026;D008545
|
T129;T191;T116;T192
|
36,290,856
|
implement primari hpv self test cervic screen program malaysia program rose lesson learnt move forward program rose remov obstacl cervic screen primari hpv base cervic screen program incorpor self sampl digit technolog ensur women link care develop base principl design think context malaysia program illustr import collabor partnership address multi facet barrier polici chang infrastructur readi implement radic new cervic screen program communiti paradigm shift cervic cancer requir monument concert effort educ healthcar provid general public short review highlight pilot project rose incorpor evid base tool rapid scale program rose idea solut adapt adopt countri notwithstand impact covid incumb countri pave road toward elimin cervic cancer pre exist footpath
|
D002583;D030361;D000086382
|
T047;T191;T067
|
36,290,855
|
use breath analysi manag lung cancer readi primetim breath analysi promis non invas method detect manag lung cancer exhal breath contain complex mixtur volatil non volatil organ compound produc end product metabol sever studi explor pattern compound postul uniqu breath signatur emit set lung cancer studi evalu use gas chromatographi mass spectrometri identifi uniqu breath signatur recent advanc field analyt chemistri machin learn gaseous chemic sens identif devic also creat detect pattern odor molecul volatil organ compound devic offer hope point care test futur sever prospect studi also explor presenc specif genom aberr exhal breath patient lung cancer altern method molecular analysi despit potenti use breath analysi larg limit translat research due methodolog issu lack standard valid pauciti larg multi center studi clear howev offer potenti non invas altern investig tumor biopsi blood sampl
|
D008175;D055549
|
T191;T109
|
36,290,854
|
associ survivorship care plan patient report satisfact confid follow cancer care provid primari care provid survivorship care plan aim facilit smooth transit tertiari primari care set primari cancer treatment complet studi sought identifi sociodemograph factor associ receiv survivorship care plan examin relationship receiv plan confid follow care deliv primari care provid cross section analysi canadian partnership cancer experi cancer patient transit studi conduct n separ adjust multinomi logist regress model assess relationship survivorship care plan follow care outcom proport survivor like receiv survivorship care plan vari numer sociodemograph medic factor cancer type colorect prostat gender male educ high school less unadjust adjust model individu receiv survivorship care plan signific higher odd felt primari care provid involv agre primari care provid understood need knew find support servic abl refer direct servic confid primari care provid could meet follow care need
|
D000359;D009369
|
T058;T191
|
36,290,853
|
prognost factor low grade glioma adult adult low grade glioma rare aggress patholog central nervous system characterist contribut patient life expect manag studi aim character identifi main prognost factor low grade glioma six year retrospect studi statist analyz demograph imag morphogenet characterist patient group appropri paramet immunohistochem test perform idh ki p nestin well fish test cdkna gene pq codelet patholog preval femal patient averag age year averag tumor volum cm produc midlin shift averag mm displac negat impact surviv presenc residu tumor result decreas surviv independ risk factor mortal posit p identifi low surviv rate cdkna mutat independ risk factor mortal identifi negat prognosi influenc associ epilepsi headach tumor volum immunoreact idh p independ factor associ mortal midlin shift presenc tumor residu cdkna gene delet amplif
|
D001932;D005910
|
T191
|
36,290,852
|
first second line treatment patient advanc hepatocellular carcinoma china systemat review chines nation guidelin recommend various system therapi patient advanc hepatocellular carcinoma hcc optim treatment select remain uncertain summar evid support system treatment chines patient advanc hcc perform systemat review use literatur search pubm embas china nation knowledg infrastructur chines scientif journal databas januari june abstract asco asco gi esmo esmo gi inclus criteria chines patient age year advanc hcc first second line system therapi evalu efficaci safeti outcom random control non random control prospect retrospect design thirti report identifi follow therapi singl agent tyrosin kinas inhibitor tki n singl agent program death pd inhibitor n chemotherapi n pd program death ligand pd l inhibitor plus tki n pd pd l inhibitor plus bevacizumab biosimilar n pd pd l inhibitor plus chemotherapi n heterogen studi preclud statist analysi data summar use tabl first line set evid support use atezolizumab sintilimab plus bevacizumab biosimilar remain insuffici evid determin optim approv tki base therapeut option activ control trial second line set lack
|
D006528;D059451;D008113
|
T121;T191
|
36,290,851
|
rapid review real world cost effect analys cancer intervent canada cost effect analysi ce analysi provid evid increment gain patient outcom cost new treatment intervent cancer care util real world data allow analys better reflect differ cost effect actual patient popul comorbid rang age oppos random control trial use restrict popul rapid review done pubm googl scholar juli relev articl summar data extract summar chang cost cad effect cancer care fund canadian govern payer system conduct statist analys examin differ mean median cost effect increment cost effect ratio icer twenti two studi select review major perform ce analysi cancer drug real world cancer drug studi signific higher cost effect non drug therapi studi util model project longer time horizon saw signific smaller icer valu treatment examin differ drug cost increas time review highlight import perform real world ce analysi cancer treatment better understand cost impact general patient popul
|
D000970;D009369
|
T121;T191;T109
|
36,290,850
|
current clinic practic precis medicin use comprehens genom profil test biliari tract cancer japan recent advanc next generat sequenc technolog comprehens genom profil cgp test design measur hundr cancer relat gene time wide introduc daili clinic practic patient whose tumor sampl fit tissu base cgp test blood base cgp test liquid biopsi avail altern option three cgp test oncoguid ncconcopanel system gene foundationon cdx gene founda tionon cdx liquid gene reimburs public insur hospit design cancer genom medicin japan biliari tract cancer preval druggabl variant relat higher compar cancer type european societi medic oncolog recommend routin use cgp test advanc biliari tract cancer guid treatment option latest nation cancer center network guidelin list eight druggabl marker ntrk fusion msi h tmb h braf fgfr fusionsrearrang idh mutat ret fusion overexpress match therapi japan match therapi four marker ntrk msi h tmb h fgfr reimburs public insur septemb progress genom profil technolog contribut improv dismal clinic outcom diseas futur
|
D057285;D001661
|
T061;T191;T091
|
36,290,849
|
precis oncolog canada convert vision realiti lesson intern program canada healthcar system like other worldwid immers process evolut attempt adapt convent framework health technolog assess hta fund model new landscap precis medicin oncolog particular need real world evid canada match necessari infrastructur technolog requir integr genom clinic data sinc healthcar system mani develop nation face similar challeng adopt solut base approach conduct search worldwid program person medicin emphasi precis oncolog search strategi includ review articl publish januari march hand search refer list relev public back decemb thirti nine initi across countri europ australasia africa america potenti lead real world data rwd clinic util oncolog biomark highlight four initi help lesson canada genom medicin franc unicanc german medic informat initi cancer id among program evalu main theme includ need collabor system support data harmon across multipl jurisdict order generat rwd precis oncolog prove accept hta bodi canada must take nation approach biomark strategi unit stakehold highest level overcom jurisdict technolog barrier
|
D009369
|
T191
|
36,290,848
|
patholog report radic prostatectomi specimen follow iccr recommend impact electron report tool implement qualiti interdisciplinari communic larg univers hospit prostat cancer repres one common malign tumor male patient germani patholog report radic prostatectomi specimen follow structur process constitut excel prototyp introduct softwar base standard structur report patholog lead report higher qualiti could creat fundament improv futur ai applic softwar base report templat use generat standard structur patholog report radic prostatectomi specimen patient treat univers hospit klinikum recht der isar technisch universitt mnchen germani narrat report nr standard structur report ssr analyz regard complet clinician satisfact report type evalu ssr show consider higher complet nr total categori signific complet ssr nr p lt clinician award overal high score nr ssr report one rater acknowledg signific higher level clariti time save compar ssr nr find highlight standard structur report radic prostatectomi specimen qualifi level report signific increas object measur content qualiti level complet implement nationwid ssr germani particular oncolog patholog serv pathologist clinician patient
|
D033183;D011468
|
T062;T054;T061
|
36,290,847
|
region survey merkel cell carcinoma plea uniform patient journey model diagnost therapeut pathway merkel cell carcinoma mcc rare aggress cutan neuroendocrin cancer usual affect elder immunosuppress sun expos area due rariti frequent unrecogn manag standard across medic center despit recent avail immunotherapi avelumab first line treatment improv prognosi even advanc stage diseas conduct purpos design survey select sampl physician work lazio region itali assess awar knowledg mcc well perspect assist diagnost therapeut pathway lazio region particular rome one import academ non academ center itali dedic diagnosi treatment skin cancer total doctor includ general practition oncologist dermatologist surgeon anatomopathologist agre part survey surgeon oncologist dermatologist thought signific updat mcc primari care physician half interviewe interest ccm train cours train clearer standard care pathway signific differ report survey particip term multidisciplinari team set mcc manag identif special center improv communic pathway among differ specialti well patient physician could benefici improv patient journey model start uniform diagnost therapeut pathway mcc patient new era immunotherapi
|
D015266;D012878
|
T191
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.